Side-by-side comparison of AI visibility scores, market position, and capabilities
A Coruña Spain pet telemedicine + AI insurance (Munich Re) across 7 European countries at €50M turnover with 75K+ insured pets; BAI trained on 800K consultations with 80% retention competing with Agria for European pet health platform.
Barkibu is an A Coruña, Spain-based pet health and insurance platform — operating across seven European countries (Spain, Germany, France, Italy, Portugal, Greece, and Finland) with approximately €50 million in annual turnover and 75,000+ insured animals — providing pet owners with AI-powered veterinary triage, telemedicine consultations with licensed veterinarians, and comprehensive pet insurance underwritten by Munich Re that processes most claims automatically within minutes through proprietary AI. Barkibu's BAI (Barkibu Artificial Intelligence), trained on over 800,000 veterinary consultations, provides 24/7 symptom assessment for dogs and cats. The company projects reaching 125,000 insured pets by end of 2025 with an 80% customer retention rate, and won the EY Scale Up Award 2025 recognizing its exceptional growth trajectory. Founded in 2015 by Pablo Pazos, Patricia Seoane, Enrique Torres, Álvaro Gutiérrez, and María González; pivoted to AI-first model in 2018. Certified B Corporation.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.